CTTH's principal asset is a unique and novel patented drug delivery technology, an orally administered, fast dissolving thin film (the "Wafer"). This technology platform will target both the human and veterinarian (pet) markets for treatment of many diseases. The Company believes that its technology... CTTH's principal asset is a unique and novel patented drug delivery technology, an orally administered, fast dissolving thin film (the "Wafer"). This technology platform will target both the human and veterinarian (pet) markets for treatment of many diseases. The Company believes that its technology will be one of the first to gain use in major markets such as pain management. The Oral Thin Film (Wafer) formulation is protected by 3 Canadian, 2 U.S. patents and over 59 patents pending or granted worldwide. 詳細を表示
Live at MJAC 2017 Saturday 2nd September - 4.05 PM on Streaming Stage F How venture capital and cryptocurrency are converging as the future of cannabis investing ...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.020375 | 52.6145900581 | 0.038725 | 0.0693 | 0.0311 | 6946 | 0.05501984 | CS |
4 | 0.011425 | 23.9643418983 | 0.047675 | 0.06985 | 0.0184 | 18482 | 0.05537359 | CS |
12 | -0.0009 | -1.5 | 0.06 | 0.08 | 0.0184 | 21432 | 0.06075606 | CS |
26 | -0.009 | -13.2158590308 | 0.0681 | 0.1 | 0.0184 | 14757 | 0.06107631 | CS |
52 | 0.0241 | 68.8571428571 | 0.035 | 0.1 | 0.01 | 19713 | 0.04365587 | CS |
156 | 0.0186 | 45.9259259259 | 0.0405 | 0.1 | 0.003 | 29761 | 0.03715433 | CS |
260 | -0.1359 | -69.6923076923 | 0.195 | 0.26 | 0.003 | 24961 | 0.05458313 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約